Coincident with a robust increase in CD133 protein (Figure 1B) and RNA (Figure 1D), Dox-treated BAKP melanoma cells exhibited a 40% reduction in pro-apoptotic markers, including cleaved active caspases-3, cleaved PARP, and active BAX, indicative of the suppression of caspase 3-mediated apoptosis by CD133 in trametinib-treated cells (Figure 1B). The gene discussed is CASP3; the disease is melanoma.